Drug Shortage Report for TARO-DOXORUBICIN LIPOSOMAL

Last updated on 2024-10-31 History
Report ID 237366
Drug Identification Number 02493020
Brand name TARO-DOXORUBICIN LIPOSOMAL
Common or Proper name Doxorubicin
Company Name TARO PHARMACEUTICALS INC
Market Status MARKETED
Active Ingredient(s) DOXORUBICIN HYDROCHLORIDE
Strength(s) 2MG
Dosage form(s) SUSPENSION
Route of administration INTRAVENOUS
Packaging size 10mL Vial
ATC code L01DB
ATC description CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2024-09-12
Estimated end date 2024-12-31
Actual end date 2024-10-15
Shortage status Resolved
Updated date 2024-10-31
Company comments US-authorized inventory will be available for shortage mitigation
Health Canada comments
Tier 3 Status Yes
Contact Address 130 EAST DRIVE
BRAMPTON, ONTARIO
CANADA L6T 1C1
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v14 2024-10-31 French Compare
v13 2024-10-31 English Compare
v12 2024-10-07 French Compare
v11 2024-10-07 English Compare
v10 2024-10-07 French Compare
v9 2024-10-07 English Compare
v8 2024-10-04 French Compare
v7 2024-10-04 English Compare
v6 2024-09-25 English Compare
v5 2024-09-19 French Compare
v4 2024-09-19 English Compare
v3 2024-09-13 English Compare
v2 2024-09-12 French Compare
v1 2024-09-12 English Compare

Showing 1 to 14 of 14